title: Pharmacogenetics and the pharmacological management of depression.
abstract: Depression is a chronic disease seen in many healthcare settings. Current pharmacological treatment options are successful in two-thirds of patients. One CYP450 enzyme, CYP2D6, is responsible for the metabolism of 30% of all drugs including many antidepressants. Phenotypes of metabolizer status affect antidepressant treatment outcomes and adverse drug reactions.
authors.affiliation: Stanford Hospitals and Clinics, USA.
authors.forename: Roseanne R
authors.initials: RR
authors.lastname: Krauter
authors.forename: Sarah S
authors.initials: SS
authors.lastname: Cook
mesh_terms: D000293:Adolescent; D000328:Adult; D000928:Antidepressive Agents / Q000378:metabolism / Q000627:therapeutic use*; D002648:Child; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics / Q000378:metabolism; D003863:Depression / Q000188:drug therapy* / Q000453:epidemiology / Q000235:genetics*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D014481:United States / Q000453:epidemiology; D055815:Young Adult
chemical_list: D000928:Antidepressive Agents; D019389:Cytochrome P-450 CYP2D6